HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Cosmetics Reform Bill Would Require FDA Regulation Of ‘Natural’ Labeling

Executive Summary

Beautycounter and Burt’s Bees are among the most vocal companies pushing for modernization of US cosmetics regulations via the proposed Personal Care Products Safety Act, which would require the FDA to establish a “natural” definition for use in product labeling.

You may also be interested in...



US FDA Convinced: Cosmetic Adverse Event Reports Aren’t Telling Whole Story

Linda Katz, director of the FDA’s cosmetics office, says to “stay tuned” for federal legislative developments in 2022, maintaining her position that voluntary adverse-event reporting paints an incomplete picture of consumers’ experience with cosmetic products across the US.

Four Federal Cosmetics Bills On Cusp Of Introduction

Ostensibly taking cues from California and lessons from previous congressional sessions, US lawmakers, NGOs and “forward-thinking cosmetics companies” seek piecemeal cosmetics reform via four federal bills slated for introduction in the coming week.

US Cosmetics Modernization Bill Relaunched, Now With Fragrance Allergen Labeling, PFAS Ban

The Personal Care Products Safety Act was reintroduced in the US Senate on 17 June with industry support including leading brands at big-name multinationals. The latest “Feinstein bill” for modernizing US cosmetics regulations purports to strengthen counterfeit product protections while floating additional requirements for fragrance allergen labeling and banning intentionally added PFAS.

Related Content

Topics

UsernamePublicRestriction

Register

RS151489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel